Key result
Cardioform Septal Occluder combined with TEER successfully closes large post-MitraClip residual commissural gap.
Why the study?
In patients with commissural mitral regurgitation, MitraClip implantation can be technically challenging and associated with higher procedural risk and less favorable outcomes.
Case Report (n=1)
Demonstrates the feasibility of using a Cardioform Septal Occluder to treat residual commissural mitral regurgitation after MitraClip implantation.
May offer bailout for residual commissural MR after MitraClip; leaves open durability, safety, and generalizability.
The MitraClip (Abbott, Santa Clara, California) transcatheter edge-to-edge repair (TEER) has become an approved therapeutic option for surgical high-risk patients with favorable anatomy and severe mitral regurgitation (MR). In patients with challenging anatomy, such as those with commissural MR, the procedure, while feasible, often demands increased technical dexterity and may be associated with higher procedural risk with less favorable outcomes. Herein, we illustrate the combined use of a TEER and Cardioform Septal Occluder (CSO) (Gore Medical Inc, Flagstaff, Arizona) to treat a large lateral commissural gap following initial Mitraclip implantation.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2022) conducted a case report in Severe mitral regurgitation with a large lateral commissural gap following initial MitraClip implantation (n=1). Combined use of TEER (MitraClip) and Cardioform Septal Occluder (CSO) was evaluated on Successful obliteration of a lateral residual commissural jet. Combined use of transcatheter edge-to-edge repair and a Cardioform Septal Occluder successfully obliterated a large lateral residual commissural gap following initial MitraClip implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: